Decapeptide-12 Modulates Sirtuin Gene Expression In Epidermal Keratinocyte Progenitors

EPO published patent application EP3601316A1 for decapeptide-12 compositions that modulate sirtuin gene expression in epidermal keratinocyte progenitors. The patent covers dermatological and cosmetic applications (A61P 17/00, A61P 17/18, A61Q 19/08) and names Escape Therapeutics, Inc. as applicant with inventors Hantash and Ubeid. Designated states cover all EU member states plus Switzerland, Norway, and other European countries.

Manufacturers in the skin care, cosmetics, and dermatological therapeutics sectors should evaluate freedom-to-operate before developing products targeting sirtuin pathway modulation in keratinocytes in designated European jurisdictions. The patent provides Escape Therapeutics with exclusive rights to the claimed decapeptide compositions and methods through the standard 20-year patent term from the filing date.